A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF).
A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF).
复制标题
一种新型雄烯二酮衍生物通过抑制巨噬细胞迁移抑制因子(MIF)诱导ROS介导的自噬并减弱骨肉瘤的耐药性
DOI:
10.1038/cddis.2014.300
复制
发表时间:
2014-08-07
影响因子:
9
通讯作者:
Zhao, Y.
中科院分区:
文献类型:
--
作者:
Liu, Y.;Zhao, L.;Ju, Y.;Li, W.;Zhang, M.;Jiao, Y.;Zhang, J.;Wang, S.;Wang, Y.;Zhao, M.;Zhang, B.;Zhao, Y.
Osteosarcoma is a common primary bone tumor in children and adolescents. The drug resistance of osteosarcoma leads to high lethality. Macrophage migration inhibitory factor (MIF) is an inflammation-related cytokine implicated in the chemoresistance of breast cancer. In this study, we isolated a novel androstenedione derivative identified as 3, 4-dihydroxy-9, 10-secoandrosta-1, 3, 5, 7-tetraene-9, 17-dione (DSTD). DSTD could inhibit MIF expression in MG-63 and U2OS cells. The inhibition of MIF by DSTD promoted autophagy by inducing Bcl-2 downregulation and the translocation of HMGB1. N-acetyl-L-cysteine (NAC) and 3-methyladenine (3-MA) attenuated DSTD-induced autophagy but promoted cell death, suggesting that DSTD induced ROS-mediated autophagy to rescue cell death. However, in the presence of chemotherapy drugs, DSTD enhanced the chemosensitivity by decreasing the HMGB1 level. Our data suggest MIF inhibition as a therapeutic strategy for overcoming drug resistance in osteosarcoma.
登录
查看更多内容
影响因子:
8.8
作者:
通讯作者:
--
影响因子:
6.7
作者:
Asare, Yaw;Schmitt, Martin;Bernhagen, Juergen
通讯作者:
Bernhagen, Juergen
影响因子:
32.4
作者:
Bucala, Richard;Donnelly, Seamas C.
通讯作者:
Donnelly, Seamas C.
影响因子:
3.4
作者:
Lin, Yanliang;Song, Xin;Qu, Yinbo
通讯作者:
Qu, Yinbo
影响因子:
4.2
作者:
Gnanasekar M;Kalyanasundaram R;Zheng G;Chen A;Bosland MC;Kajdacsy-Balla A
通讯作者:
Kajdacsy-Balla A